Ziarco Announces Appointment of Dr. Pablo Jimenez as Chief Medical Officer
(Thomson Reuters ONE) -
CANTERBURY, UK, June 8, 2015 (GLOBE NEWSWIRE) -- Ziarco Group Ltd., a clinical-
stage biopharmaceutical company focusing on inflammatory skin diseases, today
announced the appointment of Pablo Jimenez, M.D., as Chief Medical Officer,
effective immediately. Dr. Jimenez will oversee the clinical development of
Ziarco's programs targeting conditions such as atopic dermatitis and psoriasis.
"We are pleased to welcome Dr. Jimenez as our Chief Medical Officer," said Mike
Yeadon, Ph.D., President and Chief Executive Officer of Ziarco. "Dr. Jimenez has
an impressive track record as both a physician and a senior pharmaceutical
executive. His clinical development and regulatory affairs expertise will be
very important as we advance our lead compounds, ZPL-389 and ZPL-521, through
clinical studies. Furthermore, his deep knowledge of dermatology significantly
strengthens the Ziarco team, complementing our existing R&D and mechanism
expertise."
Dr. Jimenez brings to Ziarco more than 20 years of clinical development and
medical affairs experience in therapeutic areas including dermatology,
respiratory, and wound healing. Most recently, he served as Chief Medical
Officer and Executive Vice President at Celsus Therapeutics Plc, where he led
global clinical development of the company's pipeline of inflammatory disease
therapies. Previously, he served as Chief Medical Officer of Sotio, a Czech drug
development company. From 2001 to 2011, Dr. Jimenez held various roles of
increasing responsibility at Novartis Pharmaceuticals Corporation, including
Global Product Medical Director of Xolair® and Medical Affairs Head of Elidel®.
Earlier in his career, he held positions at Neuronyx, Inc., Human Genome
Sciences, Inc., and OsteoArthritis Sciences, Inc.
"I am excited to work with the Ziarco team to help advance important therapies
for inflammatory skin diseases through clinical development," said Dr. Jimenez.
"Despite recent therapeutic innovations, there remain substantial unmet needs in
conditions like psoriasis and atopic dermatitis, and Ziarco's approach to
developing novel, differentiated, small molecule oral and topical treatments for
patients shows great promise."
Dr. Jimenez earned an M.D. from the Central University School of Medicine in
Quito, Ecuador. He completed his post-doctoral research at Brown University, RI
USA, Division of Biology and Medicine.
About Ziarco
Ziarco is a clinical-stage biotechnology company developing innovative
therapeutics targeting inflammatory skin diseases. The company's lead compounds
are ZPL-389, an oral histamine H4 receptor antagonist being studied for atopic
dermatitis, and ZPL-521, a cPLA2 inhibitor being studied for inflammatory skin
disease. Ziarco investors include Biotechnology Value Fund L.P. and other
affiliates of BVF Partners L.P., Pfizer Venture Investments, New Enterprise
Associates, Lundbeckfond Ventures and Amgen Ventures.
Further information can be found at www.ziarcopharma.com.
CONTACT: Michael Yeadon
Ziarco Group Ltd
07944 475569
contact(at)ziarcopharma.com
Media:
Annie Starr
6 Degrees
(973) 415-8838
astarr(at)6degreespr.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ziarco Group Ltd. via GlobeNewswire
[HUG#1926786]
Unternehmensinformation / Kurzprofil:
Datum: 08.06.2015 - 14:00 Uhr
Sprache: Deutsch
News-ID 398860
Anzahl Zeichen: 4111
contact information:
Town:
Canterbury, Kent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 196 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ziarco Announces Appointment of Dr. Pablo Jimenez as Chief Medical Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Ziarco Group Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
